Radio-antibody & radio-ADC
Attaching a radioactive atom to an antibody, so an ADC's targeting is used to deliver radiation instead of chemotherapy.
90Y-ibritumomab (Zevalin) and 131I-tositumomab proved the concept in lymphoma but were commercially abandoned. Renewed interest: 225Ac-labelled antibodies to PSMA (J591), CD33 (lintuzumab), DLL3, HER2, and 177Lu-labelled antibodies. Long antibody half-life is both a dosimetry advantage and a marrow-toxicity problem; pretargeting and fragment approaches address it.
How it works
A chelator-conjugated antibody or fragment carries 177Lu, 225Ac, 212Pb, or 131I.
- Any ADC target becomes a radiation target
- Bystander crossfire independent of payload chemistry
- Marrow dose from circulating antibody
- Manufacturing complexity
Latest papers
topQuery for this technology: (TITLE:"radioimmunotherapy" OR ABSTRACT:"radioimmunotherapy" OR TITLE:"radioimmunoconjugate" OR ABSTRACT:"radioimmunoconjugate" OR TITLE:"radiolabeled antibody" OR ABSTRACT:"radiolabeled antibody") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Radio-antibody & radio-ADC, not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyDegrader-antibody conjugate (DAC)
Shares Efflux-agnostic therapy for mesenchymal TNBC, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
- TechnologyTROP2 PET
Shares Alpha radioligands after ADC failure, TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
- TechnologyDual-payload ADC
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
- TechnologyImmune-stimulating antibody conjugate (ISAC)
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
- TechnologyBispecific ADC
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, HER2, Antibody-drug conjugate (ADC) and the tag frontier.
- CompanyArsenal Biosciences
Shares PSMA, Renal cell carcinoma and the tag frontier.
- TechnologyMasked / conditionally active ADC
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
- CompanyAktis Oncology
Shares Targeted alpha therapy and the tag frontier.